ACURATE neo™ Aortic Valve System shows safety & efficacy results comparable to SAPIEN 3¹
Multi-centre comparison study1 between ACURATE neo Aortic Valve System and Edwards SAPIEN 3 Transcatheter Heart Valve (JACC Cardiovascular Interventions) shows comparable procedural outcomes.
- Comparable procedural outcomes
- Superior hemodynamics
- Lower new permanent pacemaker implantation rates
See Won-Keun Kim’s interview from PCR London Valves 2017 and read the publication to learn more.
Physiological assessment, use of the SYNERGY™ BP-EES Stent, IVUS guidance and complete revascularization of CTOs using contemporary CTO techniques, leads to CABG-like outcomes in patients with three-vessel disease. This is the result of the SYNTAX™ II Study, which evaluated the SYNERGY™ BP-EES Stent in a procedure-related trial involving a multitude of variables when treating patients with three-vessel disease.
ACURATE neo™: A “very safe” TAVI system providing “extremely good results in almost all patients”
In February’s issue of Cardiovascular News, Dr. C. Hengstenberg comments that with the ACURATE neo valve, “you have very high rates of implantation success and a low pacemaker rate”.
Read the article to learn more about his experience and see Prof. Dr. med. H. Möllmann presenting the ACURATE neo device as well as SAVI TF 1000 patients registry.
1. Husser O, et al. Multicenter comparison of novel self-expanding versus balloon-expandable transcatheter heart valves. JACC Cardiovasc Interv. 2017 Oct 23;10(20):2078-2087
** According to VARC-2, elevated gradients >20 mmHg are defined as mild stenosis, are assessed as Device Failure and may indicate prosthetic valve dysfunction.